Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush

Wedbush restated their neutral rating on shares of Ikena Oncology (NASDAQ:IKNA) in a research note published on Monday,RTT News reports. Wedbush currently has a $2.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Ikena Oncology in a research report on Monday, November 11th.

Ikena Oncology Price Performance

Shares of Ikena Oncology stock opened at $1.67 on Monday. The company has a market cap of $80.59 million, a PE ratio of -1.36 and a beta of 0.49. The firm has a fifty day moving average price of $1.69 and a two-hundred day moving average price of $1.69. Ikena Oncology has a fifty-two week low of $1.22 and a fifty-two week high of $2.29.

Ikena Oncology (NASDAQ:IKNA) last released its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.08. Analysts expect that Ikena Oncology will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ikena Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in Ikena Oncology by 5.6% in the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock valued at $469,000 after acquiring an additional 14,319 shares during the period. NEA Management Company LLC boosted its holdings in Ikena Oncology by 5.3% during the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after purchasing an additional 30,013 shares in the last quarter. BBR Partners LLC grew its stake in shares of Ikena Oncology by 550.0% in the 3rd quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock valued at $225,000 after purchasing an additional 110,000 shares during the period. FMR LLC raised its holdings in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after buying an additional 18,607 shares in the last quarter. Finally, BML Capital Management LLC raised its holdings in shares of Ikena Oncology by 23.6% in the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock worth $1,251,000 after buying an additional 138,174 shares in the last quarter. 75.00% of the stock is owned by institutional investors.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.